Researchers assessed the relationship between immune gene expression and genomic complexity in TNBC in a study presented at SABCS 2016.
Adopting healthy lifestyle can cut 25-year risk for the disease from 29 to 13 percent.
A recent study undertaken sought to examine the effects of chemotherapy on bladder cancer cells and possible connections to later treatment resistance.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.
Patient-derived cancer cell lines contain most of the genetic changes found in patients' tumors and could be used to determine tumor response to treatment, increasing the success rate of new personalized therapies for cancer.
A subset of tumor-associated neutrophils (TANs) has hybrid characteristics of both neutrophils and antigen-presenting cells in samples from early stage human lung cancers.
Circulating tumor DNA (ctDNA) has shorter fragment sizes than DNA fragments from healthy cells that have died, and this may increase the clinical utility of liquid biopsies.
Genetic biomarkers from tumor DNA circulating in the bloodstream could indicate the risk for recurrence of colorectal cancer and the efficacy of chemotherapy after surgery.
Researchers discovered that changes in the bone marrow needed for multiple myeloma to grow have already taken hold in patients with MGUS.
Genetic mutations affecting the immune system were identified in patients who develop more than one CRC tumor at the same time, and understanding how these cancers develop could improve therapy targeting.
The protein CBX8 uses a previously unknown mechanism to promote the origin of breast tumors, or tumorigenesis, in the most lethal forms of breast cancer, according to new research.
Researchers say it's likely that all the major genetic mutations related to colorectal cancer have been discovered.
Overall risk of developing ovarian cancer may be higher for women with certain types of human leukocyte antigen (HLA), which could underlie differences in their response to immunotherapy.
A gene expression pattern in the noncancerous tissues surrounding estrogen receptor-positive breast cancer is associated with lower 10-year survival rates.
Cell Changes in Fallopian Tubes of BRCA Mutation Carriers May Lead to Strategies for Preventing Ovarian CancerJune 13, 2016
Recognition of early changes in the Fallopian tube cells of BRCA gene mutation carriers may be key to new strategies for preventing ovarian cancer that could also reduce the need for invasive surgery.
Measurements of copies of a single gene circulating in the bloodstream allowed scientists to identify patients with stomach cancer who were most likely to respond to treatment.
The genetically engineered epothilone analog, utidelone, in combination with capecitabine significantly improved progression-free survival and objective response rates in patients with metastatic breast cancer who were heavily pretreated, compared with capecitabine alone, results of a phase 3 trial presented at the 2016 ASCO Annual Meeting have shown.
The largest database on outcomes with RET-directed therapy for RET-rearranged NSCLC to date confirms RET inhibitors are active in a proportion of patients, a study presented at the 2016 ASCO Annual Meeting has shown.
Discovery might eventually lead to better treatment for glioblastoma multiforme
Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate CancerMay 25, 2016
Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.
The Bim protein might predict which patients could be successfully treated with immunotherapy for metastatic melanoma.
No Clinical Benefit to Expanding Gene Panel Beyond Ovarian and Breast Cancer Genes in High-risk WomenMay 20, 2016
Expanding a panel of tested genes beyond the known breast and ovarian cancer-specific genes in patients with breast and ovarian cancer did not confer any clinical benefit.
The experimental treatment LOXO-101 led to remarkable improvement for a 20-month-old girl whose rare pediatric cancer did not respond to surgery or chemotherapy.
Amplification of the JAK2 gene frequently occurs in triple-negative breast cancer (TNBC), suggesting that specific inhibitors of JAK2 should be investigated in TNBC.
A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.
Researchers have pinpointed the evolutionary process cancer cells use to resist the drug LOXO-101.
Tumors of varied types of genetically defined cancer were significantly reduced by the drug LOXO-101, according to phase 1 study results.
Treatment benefit can be predicted through genotyping from blood plasma, according to several studies presented at ELCC 2016; however, plasma tests are unlikely to fully replace tissue biopsies.
Osimertinib effectively treats EGFR-mutated non-small cell lung cancer that has the T790M mutation, according to recent study findings.
- Ruxolitinib May Improve Symptom Control in Patients With CLL
- Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma
- Racial Disparities Persist in Myeloma Treatment Use
- Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma
- Comprehensive Report Looks at Benefits and Harms of Medical Cannabis
- Optimal Timing of Influenza Vaccination in Patients Receiving Chemotherapy
- Racial Disparities Persist in Myeloma Treatment Use
- Hypnosis and Its Use in Cancer Treatment
- Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases
- Patients With Breast Cancer Report More Cognitive Difficulties After Chemotherapy
- No Differences in Lung Cancer Mutations Between White, Black Patients
- Second-line Weekly Nab-paclitaxel Noninferior to Paclitaxel for Gastric Cancer
- Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
- Role of Oncology Nurse Navigators Has Evolved and Expanded in 5 Years
- Frailty Classifications Associated With Prognosis Among Older Patients
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|